Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Pharmacol Rep. 2018 Feb;70(1):184-189. doi: 10.1016/j.pharep.2017.08.014. Epub 2017 Aug 30.
Digoxin is the oldest drug used in the pharmacotherapy of heart failure (HF). However, digoxin remains an important therapeutic option for patients with persistent symptoms of HF occurring despite the implementation of standard pharmacotherapy. Digoxin concentration serum (SCD) should equal 1-2ng/ml. The aim of our study was to measure of SCD among the hospitalized patients as well as to determine the selected factors influencing the concentration of the digoxin in the blood.
The presented research was based on a retrospective analysis including 2149 patients treated with digoxin and hospitalized between 1980 and 2000. Was used for the determination of SCD automatic analyzer TDX ABBOTT GmbH - fluorescence polarization immunoassay (FPIA), with therapeutic range for digoxin of 0.8-2.0ng/ml.
Average SCD result in the study population was located within the therapeutic range and amounted 1.06ng/ml (55.7% of patients). Statistically significant differences in digoxin level were observed depending on the way of medicine administration (p=0.000001) and the daily amount (p=0.001). Moreover, statistically significant differences in digoxin level were observed depending on sex (p=0.00002).
An elevated level of digoxin was observed in the case of patients who received the medication both orally and intravenously, together with an increase in the daily amount of digoxin doses. It was confirmed that an elevated digoxin level occurs in the course of treatment in the case of women.
地高辛是心力衰竭(HF)药物治疗中使用最古老的药物。然而,地高辛仍然是持续性心力衰竭症状患者的重要治疗选择,尽管已经实施了标准药物治疗。地高辛血清浓度(SCD)应等于 1-2ng/ml。我们的研究目的是测量住院患者的 SCD,并确定影响血液中地高辛浓度的选定因素。
本研究基于回顾性分析,包括 1980 年至 2000 年间接受地高辛治疗并住院的 2149 名患者。使用自动分析仪 TDX ABBOTT GmbH - 荧光偏振免疫测定法(FPIA)测定 SCD,地高辛的治疗范围为 0.8-2.0ng/ml。
研究人群的平均 SCD 结果位于治疗范围内,为 1.06ng/ml(55.7%的患者)。根据给药方式(p=0.000001)和每日剂量(p=0.001)观察到地高辛水平存在统计学显著差异。此外,还观察到地高辛水平因性别而异(p=0.00002)。
在同时接受口服和静脉注射药物以及增加地高辛剂量的患者中,观察到地高辛水平升高。在女性治疗过程中,证实了地高辛水平升高。